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Abstract: 16 
Alkaloids including galanthamine (1) and codeine (2) are reported to be positive allosteric 17 
modulators of nicotinic acetylcholine receptors (nAChRs) but the binding sites responsible 18 
for this activity are not known with certainty. Analogues of galanthamine (1), codeine (2) and 19 
morphine (3) with reactivity towards cysteine thiols were synthesised including conjugated 20 
enone derivatives of the three alkaloids 4-6 and two chloro-alkane derivatives of codeine 7 21 
and 8. The stability of the enones was deemed sufficient for use in buffered aqueous solutions 22 
and their reactivity towards thiols was assessed by determining the kinetics of reaction with a 23 
cysteine derivative. All three enone derivatives were of sufficient reactivity and stability to be 24 
used in covalent trapping, an extension of the substituted cysteine accessibility method 25 
(SCAM), to elucidate the allosteric binding sites of galanthamine and codeine at nAChRs. 26 
  27 
1 
Introduction: 28 
Galanthamine (1, Figure 1) is an alkaloid present in many plant species from the 29 
Amaryllidaceae family including Galanthus, Narcissus and Leucojum. Initially used as a 30 
curare reversal agent in anaesthetic practice and to assist in recovery from paralysis [1], it is 31 
currently approved in many countries world-wide to provide symptomatic relief in 32 
Alzheimer’s disease [2]. Galanthamine (1) has a dual mode of action on the cholinergic 33 
system with the overall effect of increasing nicotinic acetylcholine receptor (nAChR) activity 34 
[1a, 3]. It increases acetylcholine (ACh) levels by competitively inhibiting acetylcholinesterase 35 
(AChE), the enzyme responsible for ACh hydrolysis (IC50 ≈ 3 μM) [4]. At low concentrations 36 
galanthamine (0.02–2 μM) has been reported to be a positive allosteric modulator (PAM) of 37 
nAChRs, increasing the response of the receptor to endogenous ACh. However, at higher 38 
concentrations (>10 μM) it acts as a nAChR inhibitor [5]. While the binding site of 39 
galanthamine (1) on the AChE enzyme is well established [6], its binding site within nAChRs 40 
has not been located with certainty, although a number of potential sites have been proposed 41 
[7]. The structurally similar alkaloid codeine (2), used as an analgesic and found in the opium 42 
poppy (Papaver somniferum), has also been reported to be a PAM of nAChRs without 43 
inhibiting AChE [8]. Based on detailed studies of structure and hydrogen bonding properties, 44 
it has been proposed that codeine (2) binds at the same location as galanthamine (1) on 45 
nAChRs [9]. In contrast to codeine, morphine (3) is not a PAM of nAChRs [8].  46 
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Figure 1: Structures of galanthamine (1), codeine (2) and morphine (3). 48 
In the absence of high-resolution structural information, the identification and validation of 49 
allosteric binding sites in proteins like nAChRs presents considerable challenges. Approaches 50 
include probing ligand receptor interactions through site-directed mutagenesis or ligand 51 
competition experiments within the substituted cysteine accessibility method (SCAM) [10]. 52 
However, these approaches provide indirect evidence of binding site location and may be 53 
compromised by conformational changes influencing ligand interaction at some distance 54 
from the putative site under investigation [11]. More direct evidence of allosteric ligand 55 
2 
binding can be achieved by photoaffinity labelling of receptors using photoactive ligands [12]. 56 
However, this method typically requires high protein concentrations to minimise non-57 
selective labelling and can be complicated by the broad range of reactivity associated with 58 
different amino acid sidechains [13].  59 
Covalent trapping is an affinity labelling method with the potential to provide concrete 60 
evidence of allosteric binding sites [14]. The technique extends the SCAM and employs 61 
cysteine mutagenesis in combination with thiol-reactive ligands. The formation of a covalent 62 
bond between the ligand and binding site results in an irreversible change in receptor function 63 
that can generally be detected by sensitive analytical techniques such as two electrode voltage 64 
clamp electrophysiology [10]. Covalent trapping has been successfully applied in the neuronal 65 
nAChR field to covalently attach methyllycaconitine (MLA) in the α7-α7 interface of the α7 66 
nAChR [15], to identify the binding site of small analogues of MLA at α7 and α4β2 nAChRs 67 
[15-16], and to demonstrate that MLA binds at the α4-α4 interface of (α4)3(β2)2 nAChRs at a 68 
site distinct from the canonical α4-β2 interface agonist binding site [17].  69 
The development of thiol-reactive probes for covalent trapping is subject to a range of 70 
constraints. Ideally, the thiol-reactive analogue will closely resemble the parent ligand so that 71 
it binds at the same allosteric site and even exerts the same biological activity. Further, the 72 
thiol-reactive ligand must, after equilibrium binding, undergo reaction with a suitably 73 
positioned cysteine residue to irreversibly forge the covalent bond. It follows that the probe 74 
reactivity must be adequate to promote covalent trapping, but not so great as to impose 75 
solution instability or non-selective reactions with the receptor protein. In order to investigate 76 
the allosteric binding sites for galanthamine (1) and codeine (2) we targeted the conjugated 77 
enone analogues narwedine (4, Figure 2), codeinone (5) and morphinone (6), together with 78 
the mustard 7 and benzyl chloride 8 derivatives of codeine (2). These derivatives provide a 79 
topologically varied range of minor structural changes to the parent ligands. The details of 80 
their synthesis and the evaluation of their reactivity by examining the solution kinetics of 81 
their reaction with N-acetyl-L-cysteine methyl ester are presented herein. 82 
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Figure 2: Structures of the thiol-reactive analogues. 84 
Results and Discussion: 85 
Synthesis of conjugated enone analogues 86 
Racemic narwedine (4) was obtained from the oxidation of galanthamine (1) with Dess-87 
Martin periodinane (DMP) in 71 % yield (Scheme 1). The enantiomeric purity was estimated 88 
by comparison of the optical rotation with the optical rotation of resolved samples reported in 89 
the literature [18]. An enantiomerically enriched sample of narwedine (4), with an estimated 90 
79:21 enantiomeric ratio could be obtained using manganese dioxide as the oxidant. Under 91 
basic conditions and in protic solvents, including those commonly used to work-up DMP 92 
oxidations, narwedine (4) can racemise. Following a base promoted retro-Michael reaction 93 
the resulting phenoxide ion can add to either of the two alkenes of the resulting dienone 94 
intermediate to regenerate either enantiomer of narwedine (4). Under milder conditions such 95 
as those employed in the oxidation with manganese dioxide partial racemisation results from 96 
the inherent basicity of narwedine (4) itself. Given the facile racemisation of narwedine in 97 
protic solvents, racemic narwedine was deemed suitable to undertake the solution kinetics for 98 
this study. If required, enantiomerically pure narwedine can be obtained by crystallisation 99 
involving dynamic kinetic resolution as performed in the industrial synthesis of galanthamine 100 
[18].  101 
When codeine (2) was oxidised with freshly prepared DMP, codeinone (5) [19] was obtained 102 
as the sole product in 81 % yield. It was observed that when aged samples of DMP were used 103 
for the oxidation a small portion of the codeinone (5) was further oxidised to afford 14-104 
hydroxycodeinone, identified by NMR comparison with the literature [20]. This over-oxidation 105 
is believed to result from traces of 2-iodoxybenzoic acid formed when DMP is hydrolysed by 106 
adventitious moisture.  107 
4 
Attempts to directly oxidise morphine (3) to morphinone (6) led to decomposition and the 108 
desired product could not be isolated from reaction mixtures. Instead, a route involving 109 
protection of the phenol was employed. Morphine (3) was selectively protected as the TBS 110 
ether at the phenolic position to afford compound 9 [21] in 30 % yield. Oxidation of the allylic 111 
alcohol with DMP afforded the protected enone 10 (88%) [21], which was then deprotected 112 
with aqueous hydrochloric acid to give morphinone (6) [21b] in a yield of 70%. 113 
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Scheme 1: Synthesis of narwedine (4), codeine (5) and morphinone (6). 115 
A minor impurity detected in samples of codeinone and morphinone resulted from 116 
deconjugation of the enone (Scheme 2). In aqueous solutions, an equilibrium is established 117 
between codeinone (5) or morphinone (6) and their deconjugated isomers 11 and 12 which 118 
are unreactive towards thiol nucleophiles. While the equilibrium between codeinone (5) and 119 
its deconjugated isomer 11 is well known [22], the corresponding equilibrium for morphinone 120 
has not been reported in the literature. Based on the 1H NMR analysis of the product 121 
mixtures, the deconjugated enone isomers 11 and 12 formed an estimated 5-10% of the final 122 
products. The presence of this non-reactive impurity could be readily accounted for in the 123 
subsequent kinetic analysis. 124 
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Scheme 2: Deconjugation of codeinone (5) and morphinone (6) in aqueous solution. 126 
Synthesis of chlorinated analogues 127 
The codeine mustard 7 was prepared in two steps from codeine (2) as shown in Scheme 3. 128 
Codeine (2) was treated with α-chloroethyl chloroformate (ACE-Cl) to generate an 129 
intermediate carbamate that was hydrolysed to norcodeine (13) [23] in methanol in 82 % yield 130 
over two steps. In the absence of base, the initial reaction with ACE-Cl was very slow with 131 
residual codeine observed after three days. This may result from generation of acid within the 132 
reaction mixture rendering the tertiary amine less nucleophilic. Addition of solid sodium 133 
bicarbonate to the reaction mixture resulted in a significant increase in rate and complete 134 
conversion was achieved in one day. Removal of the base prior to methanolysis was required 135 
to avoid the formation of a by-product, believed to be the methyl carbamate.  136 
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Scheme 3: Synthesis of codeine mustard 7. 138 
Synthesis of the codeine mustard 7 via reductive amination with chloroacetaldehyde was 139 
complicated by the ready formation of the reactive aziridinium ion 14 through intramolecular 140 
nucleophilic substitution. Reductive amination of norcodeine (13) with sodium 141 
cyanoborohydride as the reducing agent failed to generate the desired mustard 7. Instead, a 142 
product with mass spectrum consistent with the ethyl bridged dimer was generated as the sole 143 
product. Reductive amination with sodium triacetoxyborohydride afforded the codeine 144 
6 
mustard 7 as the sole product in 85 % yield. Attempts to obtain the 1H-NMR spectrum of the 145 
codeine mustard 7 in deuterated methanol led to the rapid formation of the d3-methyl ether 146 
product (t½ ≈ 2 h). Additionally, dissolving the compound in aqueous buffer resulted in rapid 147 
hydrolysis generating the amino alcohol (t½ ≈ 30 min). Based on this reactivity it was 148 
determined that the codeine mustard 7 would be too unstable to be useful as a reactive probe 149 
in covalent trapping experiments.  150 
While the targeted benzyl chloride 8 derivative of codeine could not be prepared in pure 151 
form, a protected analogue 15 was prepared in 5 steps from morphine (Scheme 4). Selective 152 
triflation of the phenol afforded the morphine triflate 16 [24] in 82 % yield, which was then 153 
protected as the TBS ether 17 (90 %) [25]. Subsequent palladium catalysed carbonylative 154 
coupling gave methyl ester 18 (72%), which was reduced to give the benzyl alcohol 19 in 84 155 
% yield. The protected benzyl chloride derivative 15 was afforded by treatment with thionyl 156 
chloride (86%). However, attempts to deprotect the silyl ether to afford the desired benzyl 157 
chloride derivative 8 failed due to the reactivity of the benzyl chloride moiety. Deprotection 158 
with aqueous hydrochloric acid, as was applied in the synthesis of morphinone, led to 159 
complete hydrolysis of the benzyl chloride. Deprotection using tetrabutylammonium fluoride 160 
(TBAF) led to an inseparable and complex mixture of products. Finally, it was observed that 161 
dissolving the protected benzyl chloride 15 in deuterochloroform led to slow dimerisation and 162 
dissolving in aqueous buffer led to the rapid formation of the benzyl alcohol (t½ < 1 min). 163 
Based on these results it was determined that even if the benzyl chloride derivative 8 could be 164 
obtained through desilylation, it would be too unstable to be useful as a thiol-reactive probe 165 
and its synthesis was not pursued further. 166 
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Scheme 4: Synthesis of the protected benzyl chloride 15 from morphine (3)  168 
Reaction Kinetics 169 
In this work reactivity of the reactive probe candidates was evaluated by monitoring the 170 
solution kinetics of the reaction with N-acetyl-L-cysteine methyl ester (20, Scheme 5a). The 171 
comparison of solution phase data with that obtained from covalent trapping experiments 172 
may be used to establish future guidelines on desired levels of the reactivity and stability for 173 
reactive probes. In this manner, compounds that react are likely to react unselectively or too 174 
slowly with thiols can be excluded before deploying resources on the covalent trapping 175 
experiment. Such investigations could also aid in the design of new reactive probes or 176 
provide information on the stereochemical course of reactions that could aid in the selection 177 
of cysteine mutants for the covalent trapping experiments. 178 
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Scheme 5: (a) Reaction of codeinone (5) or morphinone (6) with N-acetyl-L-cysteine methyl 180 
ester (20) to form adducts 21 or 22. (b) Selected 1H NMR coupling constants and nOes for 181 
adduct 21 (boxed section). 182 
The pseudo first order kinetics of the reaction between codeinone (5) or morphinone (6) and a 183 
20-fold excess of N-acetyl-L-cysteine methyl ester (20) were studied under conditions as 184 
close as possible to those employed in covalent trapping experiments. Reactions were 185 
conducted in triplicate with enone concentration determined by LCMS. Due to the enone 186 
tautomerisation discussed earlier (Scheme 2) the stock solutions of codeinone (5) or 187 
morphinone (6) contained a small amount of the deconjugated isomers 11 and 12 which 188 
eluted together with their respective conjugated enones. Since the deconjugated isomers 11 189 
and 12 do not react with thiols and the rate of tautomerisation was observed to be slow 190 
relative to the rate of addition, the exponential decay relationship for total codeinone (5 + 11) 191 
or morphinone (6 + 12) concentration has a non-zero asymptote corresponding to the 192 
concentration of the deconjugated isomers. The relationship between total codeinone or 193 
morphinone concentration and time is therefore given by Equation 1 where [A]0 is the initial 194 
concentration of the conjugated enone, [B] is the concentration of the deconjugated enone 195 
and kobs is the pseudo-first order rate constant: 196 
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑒𝑒𝑒𝑒𝑡𝑡𝑒𝑒𝑒𝑒 𝑐𝑐𝑡𝑡𝑒𝑒𝑐𝑐𝑒𝑒𝑒𝑒𝑡𝑡𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐𝑡𝑡𝑒𝑒 = [𝐴𝐴]0𝑒𝑒−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡 + [𝐵𝐵] 197 
Equation 1 198 
The kinetics of the reaction between narwedine (4) and a 20-fold excess of N-acetyl-L-199 
cysteine methyl ester (20) were monitored under slightly different conditions. Since the 200 
reaction was much slower under buffered aqueous conditions and concentrations (25 μM) 201 
9 
typically used during LC-MS analysis of codeinone or morphinone, the reaction was 202 
monitored using 1H-NMR which allows for much higher concentrations (mM). Reactions 203 
were conducted in triplicate in deuterated methanol. Unlike codeinone (5) and morphinone 204 
(6), narwedine (4) does not isomerise to an unreactive product and the relationship between 205 
the concentration of narwedine (4) and time is a simple exponential decay. 206 
A plot of the total codeinone concentration over time is shown in Figure 3. The 207 
corresponding plots for total morphinone (6) and narwedine (4) can be found in the 208 
supporting information. The starting concentration of codeinone (5) was 25 μM and the 209 
concentration of N-acetyl-L-cysteine methyl ester (20) was 500 μM. The observed pseudo-210 
first order rate constant (kobs) is (2.0 ± 0.1) × 10–3 s–1 (Table 1). The corresponding second 211 
order rate constant (k) is 4.0 ± 0.2 M–1 s–1. Morphinone provided similar results. By 212 
comparison, the second order rate constant for the reaction of SCAM reagent 2-aminoethyl 213 
methanethiosulfonate (MTSEA) with 2-mercaptoethanol is reported as (7.6 ± 0.4) × 104 M–1 214 
s–1 under similar conditions (58 mM sodium phosphate buffer, pH 7.0, 20 °C).[10] With a 215 
starting concentration of 10 mM narwedine (4) and 200 mM N-acetyl-L-cysteine methyl ester 216 
the observed pseudo-first order rate constant (kobs = [2.26 ± 0.04] × 10–4 s–1) corresponded to 217 
a significantly smaller second-order rate constant (k) of (1.13 ± 0.02) × 10–3 M–1 s–1. The 218 
second order rate constants for codeinone (5) and morphinone (6) are three orders of 219 
magnitude larger. Based on solution stability and reactivity of the enones, they appear 220 
suitable for use as thiol-reactive probes. The proposed deployment of enones as probes in 221 
covalent trapping also receives support from the observation of covalent attachment between 222 
the structurally distinct enone natural products gracilioether B and plakilactone C and the 223 
cysteine containing binding site of the peroxisome proliferator-activated receptor γ (PPARγ) 224 
under physiologically relevant conditions.[26]  225 
10 
 226 
Figure 3: Plot of concentration of total codeinone (5 + 11) during the reaction with N-acetyl-227 
L-cysteine methyl ester (20) with a starting concentration of 25 μM (10 mM HEPES buffer, 228 
pH 7.5, 20 °C) 229 
Although the kinetic investigations provide useful information regarding probe stability and 230 
relative reactivity, care should be exercised in extrapolating the magnitudes of the second 231 
order rate constants k measured in solution with the performance in covalent trapping 232 
experiments with nAChR mutants. The rate constants measured in this work involve a second 233 
order reaction of a reactive probe (P) and a cysteine derivative (C, Scheme 6a). The covalent 234 
trapping experiment of a thiol-reactive probe (P) with a cysteine mutant receptor (R) is 235 
characterised by equilibrium binding followed by irreversible covalent bond formation, 236 
trapping the ligand within the binding site (Scheme 6b). This kinetic scheme provides a basis 237 
for understanding covalent trapping data and in part is determined by the absolute reactivity 238 
of the probe for the cysteine mutant. However, the rate constant k2 defines the first order 239 
reaction of the reactive probe-receptor complex ([P•R]) involving covalent bond formation 240 
and cannot be directly compared with the second order rate constant k measured in solution. 241 
The formation of a probe-receptor complex will influence the rate of reaction due to 242 
proximity effects. If the cysteine residue in the receptor binding site is positioned favourably 243 
for reaction with the probe, the rate of covalent bond formation may be significantly greater 244 
than expected based on measures of absolute reactivity. Conversely, if the cysteine residue in 245 
the binding site is in an unfavourable position for reaction with the probe, the rate of covalent 246 
trapping may be significantly lower. 247 
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Scheme 6: (a) Second order addition of reactive probe (P) with a cysteine derivative (C); (b) 249 
Kinetic scheme for the covalent trapping of a thiol-reactive probe (P) by a cysteine mutant 250 
receptor (R).  251 
The stereochemistry of the adduct 21 was determined by NMR analysis of a pure sample 252 
obtained in 94 % yield from the reaction of codeinone (5) with N-acetyl-L-cysteine methyl 253 
ester (20) in methanol. The 8S-stereochemistry observed (Scheme 5) was that predicted based 254 
on steric considerations. These alkaloid derivatives adopt a T-shaped conformation with the 255 
piperidine and cyclohexenone rings forming a plane perpendicular to the furan and phenyl 256 
rings. As a result the lower si face of the cyclohexenone ring is blocked by the steric bulk of 257 
the furan and phenyl rings, favouring addition to the top re face and leading to an equatorial 258 
disposition of the cysteine substituent in the cyclohexanone ring. The stereochemistry of 259 
adduct 21 was supported by consideration of coupling constants and nOe interactions of 260 
protons in the cyclohexanone ring. The H8 proton appeared as a triplet of doublets with two 261 
large coupling constants (13.2 Hz) and one small coupling constant (2.4 Hz). The large 262 
couplings are consistent with axial-axial couplings between the H8 proton and the adjacent 263 
H14 and H7α protons. The smaller coupling is consistent with an axial-equatorial coupling 264 
between the H8 proton and the adjacent H7β proton. The observed nOe interactions were also 265 
consistent with the proposed structure. 266 
Table 1: Experimentally determined parameters for the integrated rate equations. 267 
Enone [A]0 (M) [B] (M) kobs (s–1) k (M–1s–1) 
codeinonea (26 ± 1) × 10-6 (1.2 ± 0.2) × 10-
6 
(2.0 ± 0.1) × 10–3 4.0 ± 0.2 
morphinonea (21 ± 1) × 10-6 (1.3 ± 0.2) × 10-
6 
(1.8 ± 0.1) × 10–3 3.6 ± 0.2 
narwedineb (8.8 ± 0.2) × 10-
3 
-c (2.26 ± 0.04) × 10–
4 
(1.13 ± 0.02) × 10–
3 
a HEPES buffer (10 mM), pH 7.5, 20 °C; b deuterated methanol, 25 °C; c Not applicable. 268 
The 8S-adduct 21 had been reported in the literature previously, reacting codeinone (5) with 269 
N-acetyl-L-cysteine methyl ester (20) in acetonitrile under mildly basic conditions [27]. 270 
12 
However, the NMR data and optical rotation reported differed considerably from that 271 
obtained for compound 21 prepared in methanol solution as described in this work. 272 
Employing the previously reported experimental procedure [27] provided a sample with 273 
identical 1H NMR and optical rotation to that prepared in methanol. A comparison of the 1H 274 
and 13C NMR data for the two reports is given in the supporting information together with 275 
copies of 1D and 2D NMR spectra.  276 
The reaction between racemic narwedine (4) and enantiomerically pure N-acetyl-L-cysteine 277 
methyl ester (20) afforded a more complex stereochemical outcome. Given the racemic 278 
nature of the enone under investigation, diastereomers resulting from the two alkaloid 279 
enantiomers were expected. In addition, the enone double bond provides two faces accessible 280 
for nucleophilic addition leading to the formation of up to four diastereomers. Two separable 281 
diastereomers were obtained in 38% and 43% yield from the reaction of narwedine (4) with 282 
N-acetyl-L-cysteine methyl ester (20) in methanol. These showed similar 1H and 13C NMR 283 
spectra. Based on the steric considerations and NMR analysis we tentatively assigned these 284 
adducts as diastereomers 23a and 23b arising from addition cis to the conformationally 285 
constrained and planar aromatic ring of narwedine (4).[28] It was not possible to assign the 286 
relative configuration between the alkaloid core and the tethered amino acid. A discussion of 287 
the stereochemical assignment of the two diastereomers together with copies of 1D and 2D 288 
NMR spectra are provided in the supporting information.  289 
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Figure 4: Structures of the two diastereomers formed when racemic narwedine (4) reacts 291 
with N-acetyl-L-cysteine methyl ester (20)  292 
Conclusion: 293 
Thiol-reactive analogues of galanthamine (1), codeine (2) and morphine (3) were synthesised 294 
as probes to study the binding site of these compounds at nAChRs. These included the 295 
conjugated enone derivatives of all three alkaloids 4-6, a mustard derivative of codeine 7 and 296 
a protected benzyl chloride derivative of codeine 15. The chlorinated derivatives of codeine 7 297 
and 8 were deemed too reactive for use in covalent trapping studies, due to instability in 298 
13 
aqueous buffer. The kinetics of the reaction between the conjugated enones and N-acetyl 299 
cysteine methyl ester were studied as a model for their reactivity with cysteine residues in 300 
mutant nAChRs. Codeinone (5) and morphinone (6) reacted exclusively at the least hindered 301 
face of the cyclohexenone ring with second order rate constants (k) of 4.0 ± 0.2 M–1 s–1 and 302 
3.6 ± 0.2 M–1 s–1 respectively. Narwedine (4) reacted at both faces of the cyclohexenone ring 303 
with a second order rate constant (k) of (1.13 ± 0.02) × 10–3 M–1 s–1. Based on the solution 304 
stability and thiol reactivity the three enone derivatives appear suitable as thiol-reactive 305 
probes in covalent trapping experiments. Covalent trapping experiments will be pursued in 306 
the near future and the results of these studies will be reported in due course.  307 
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Experimental: 313 
General Experimental: 314 
All reactions were performed under an atmosphere of nitrogen unless otherwise stated. 315 
Codeine and morphine were supplied by Tasmanian Alkaloids, galanthamine hydrobromide 316 
was supplied by Janssen Pharmaceutica, dichloroethane was purchased from Ajax Finechem, 317 
all other solvents were purchased from Merck, all other chemicals were purchased from 318 
Sigma Aldrich. Reaction temperatures were controlled using oil baths for temperatures 319 
greater than room temperature or standard ice baths for 0 °C. Removal of solvent in vacuo 320 
refers to the concentration of samples by rotary evaporation under reduced pressure. Melting 321 
points were determined using an Optimelt automated melting point system. Optical rotations 322 
were determined using a Perkin-Elmer Model 343 Polarimeter set at the 589 nm sodium D 323 
line, in a 1.00 dm cell at 20 °C. The specific rotation is reported along with the concentration 324 
in g/100 mL and solvent. Infrared (IR) absorption spectra were obtained using a Perkin-Elmer 325 
Spectrum One FTIR spectrometer. All compounds were analysed as a thin-film on NaCl 326 
plates. Key absorbance bands are reported in wavenumbers (cm-1). Nuclear Magnetic 327 
Resonance (NMR) spectra were obtained on a Bruker 400 (400 MHz) or a Bruker 800 (800 328 
MHz) NMR spectrometer. Samples were analysed at room temperature and dissolved in 329 
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deuterated chloroform (CDCl3). The machine was operated at 400 MHz or 800 MHz for 1H-330 
NMR or 100 MHz for 13C-NMR. Chemical shifts (δ) are reported in ppm relative to TMS (δ 331 
= 0) and the splitting of 1H-NMR peaks are reported with the following codes; s = singlet, d = 332 
doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of 333 
triplets, dm = doublet of multiplets, td = triplet of doublets, ddd = doublet of doublet of 334 
doublets, br = broad. Where two protons are attached to the same carbon they are assigned as 335 
axial or equatorial where appropriate. Where axial or equatorial assignment is not appropriate 336 
the protons are assigned as α (top face) or β (bottom face). Assignment of chemical shifts (δ) 337 
is based on analysis of COSY, NOESY, HMBC and HSQC NMR. Low-resolution mass 338 
spectrometry (LRMS) and high-resolution mass spectrometry (HRMS) were performed using 339 
positive electron ionisation (EI) on a Micromass VG Autospec mass spectrometer, or using 340 
positive electrospray ionisation (ESI) on a Micromass ZMD ESI-Quad (LRMS) or a Waters 341 
LCT Premier XE mass spectrometer (HRMS).  342 
General procedure for Michael addition reaction:  343 
A solution of the enone (1 eq) and N-acetyl-L-cysteine methyl ester (2 eq) were dissolved in 344 
methanol (100 µL / mg of enone) and the resulting solution was stirred at room temperature 345 
overnight. The following morning the solvent was removed in vacuo to give the crude 346 
compound, which was purified by flash chromatography. 347 
Codeinone – N-acetyl-L-cysteine methyl ester adduct: 348 
The general procedure was applied to codeinone (5, 20 mg, 67 µmol), purifying by flash 349 
chromatography (9:1 chloroform : methanol), to yield the title compound 21 (30 mg, 94%) as 350 
a white solid, mp: 86-88 °C. [𝛼𝛼]𝐷𝐷20 +22 (c 1.0, CHCl3), (lit [27] [𝛼𝛼]𝐷𝐷20 -127 (c 0.5, CHCl3)). 351 
νmax (NaCl)/cm–1 3287, 1731, 1667, 1277, 1259. δH (800 MHz, CDCl3) 6.70-6.71 (m, 1H, 352 
H2), 6.67-6.69 (m, 1H, H1), 6.32 (d, br, J = 6.8 Hz, 1H, H3’), 4.81 (m, 1H, H2’), 4.69 (s, 1H, 353 
H5), 3.89 (s, 3H, H3a), 3.63 (s, br, 1H, H9), 3.46 (s, 3H, H1a’), 3.04 (dd, J = 14.0 Hz, 4.4 Hz, 354 
1H, H2a’), 3.01 (d, J = 18.8 Hz, 1H, H10α), 2.98 (dd, J = 14.0 Hz, 4.0 Hz, 1H, H2a’), 2.70 (dd, J 355 
= 13.2 Hz, 2.4 Hz, 1H, H7β), 2.57 (d, br, J = 11.6 Hz, 1H, H16eq), 2.53 (t, J = 13.2 Hz, 1H, 356 
H7α), 2.44-2.49 (4H, m, H14, H17a), 2.34 (dd, J = 18.4 Hz, 5.2 Hz, 1H, H10β), 2.30 (td, J = 12.8 357 
Hz, 2.4 Hz, 1H, H8), 2.20 (td, J = 12.0 Hz, 2.8 Hz, 1H, H16ax), 2.06 (td, J = 12.0 Hz, 4.0 Hz, 358 
1H, H15ax), 1.97 (s, 3H, H3b’), 1.82 (d, br, J = 12.0 Hz, 1H, H15eq). δC 204.8, 170.9, 169.9, 359 
145.2, 143.1, 126.8, 126.5, 120.4, 115.0, 91.5, 57.0, 56.9, 52.6, 52.3, 47.5, 47.4, 47.3, 47.2, 360 
15 
43.0, 41.6, 35.7, 31.5, 23.2, 19.3. m/z (EI) = 474 (M+•, 15), 299 (35), 298 ([M–C6H10NO3S]+, 361 
100), 297 ([M–C6H11NO3S]+•, 30). m/z (EI) = 474.1827 (M+•, C24H30N2O6S gives 474.1825) 362 
The literature procedure [27] was applied to codeinone (5, 20 mg, 67 µmol) with 2 eq of N-363 
acetyl-L-cysteine methyl ester and 6 eq of sodium bicarbonate to give a yellow oil, [𝛼𝛼]𝐷𝐷20 +31 364 
(c 1.0, CHCl3), purified by flash chromatography (9:1 chloroform : methanol), to yield the 365 
title compound 21 (14 mg, 44%) as a white solid, mp: 90-92 °C. [𝛼𝛼]𝐷𝐷20 +23 (c 1.0, CHCl3). 366 
Narwedine – N-acetyl-L-cysteine methyl ester adducts: 367 
The general procedure was applied to narwedine (4, 50 mg, 175 µmol), purifying by flash 368 
chromatography (9:1 chloroform : methanol), to yield adducts 23a (or 23b) (31 mg, 38 %) 369 
and adducts 23b (or 23a) (35 mg, 43 %) as colourless oils. 370 
Adduct 23a (or 23b). [𝛼𝛼]𝐷𝐷20 +3 (c 0.4, CHCl3). νmax (NaCl)/cm–1 3289, 1744, 1721, 1675, 371 
1286, 1204. δH (800 MHz, CDCl3) 6.68 (d, J = 8.0 Hz, 1H, H2), 6.64 (d, J = 8.0 Hz, 1H, H1), 372 
6.29 (d, br, J = 7.6 Hz, 1H, H3’), 4.86 (ddd, J = 7.6 Hz, 5.6 Hz, 4.0 Hz, 1H, H2’), 4.68 (t, J = 373 
2.8 Hz, 1H, H4a), 4.11 (d, J = 14.8 Hz, 1H, H12β), 3.83 (s, 3H, H3a), 3.78 (s, 3H, H1a’), 3.63 (d, 374 
J = 14.8 Hz, 1H, H12α), 3.58 (s, br, 1H, H8), 3.41 (t, br, J = 13.6 Hz, 1H, H10β), 3.14 (dd, J = 375 
13.6 Hz, 4.0 Hz, 1H, H2a’), 3.10 (d, br, J = 14.4 Hz, 1H, H10α), 2.98-3.01 (m, 1H, H5β), 2.94-376 
2.96 (m, 1H, H5α), 2.88 (dd, J = 13.6 Hz, 5.6 Hz, 1H, H2a’), 2.58 (dd, J = 16.8 Hz, 3.6 Hz, 1H, 377 
H7β), 2.50 (dd, J = 16.8 Hz, 2.8 Hz, 1H, H7α), 2.32 (s, 3H, H11a), 2.09 (t, br, J = 14.0 Hz, 1H, 378 
H9α), 2.07 (s, 3H, H3b’), 1.96 (dd, J = 14.0 Hz, 3.2 Hz, 1H, H9β). δC 206.3, 171.1, 170.0, 146.8, 379 
144.0, 131.7, 129.5, 123.0, 111.7, 87.9, 60.0, 56.1, 55.3, 53.0, 51.7, 51.4, 44.3, 41.8, 41.1, 380 
40.2, 33.9, 32.8, 23.2. m/z (EI) = 462 (M+•, < 1), 286 (35), 285 ([M–C6H11NO3S]+•, 100), 242 381 
(40), 216 (25), 199 (25), 174 (45), 118 (20), 88 (45), 76 (50). m/z (ESI) = 463.1904 ([M+H]+, 382 
C23H31N2O6S gives 463.1903). 383 
Adduct 23b (or 23a). [𝛼𝛼]𝐷𝐷20 +50 (c 0.4, CHCl3). νmax (NaCl)/cm–1 3271, 1720, 1659, 1286, 384 
1204. δH (800 MHz, CDCl3) 6.69 (d, J = 8.0 Hz, 1H, H2), 6.64 (d, J = 8.0 Hz, 1H, H1), 6.19 385 
(d, J = 7.6 Hz, 1H, H3’), 4.78 (td, J = 7.6 Hz, 4.0 Hz, 1H, H2’), 4.69 (t, J = 2.8 Hz, 1H, H4a), 386 
4.19 (d, J = 14.8 Hz, 1H, H12β), 3.84 (s, 3H, H3a), 3.77 (s, 3H, H1a’), 3.67 (s, br, 1H, H8), 3.63 387 
(d, J = 14.8 Hz, 1H, H12α), 3.39 (t, br, J = 13.2 Hz, 1H, H10β), 3.15 (dd, J = 13.6 Hz, 4.0 Hz, 388 
1H, H2a’), 3.09 (d, br, J = 14.4 Hz, 1H, H10α), 3.03 (dd, J = 18.4 Hz, 2.8 Hz, 1H, H5α), 2.95 389 
(dd, J = 18.4 Hz, 2.8 Hz, 1H, H5β), 2.78 (dd, J = 13.6 Hz, 7.6 Hz, 1H, H2a’), 2.61 (dd, J = 17.2 390 
Hz, 3.6 Hz, 1H, H7β), 2.52 (dd, J = 17.2 Hz, 2.8 Hz, 1H, H7α), 2.34 (s, 3H, H11a), 2.08-2.12 391 
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(m, 4H, H9α, H3b’), 1.98 (dd, J = 14.0 Hz, 3.2 Hz, 1H, H9β). δC 206.0, 171.2, 170.2, 146.8, 392 
144.0, 131.7, 129.3, 123.1, 111.7, 88.0, 59.9, 56.1, 55.3, 53.2, 51.3, 51.2, 43.3, 42.1, 40.8, 393 
40.1, 33.3, 33.0, 23.4. m/z (EI) = 462 (M+•, < 1), 286 (35), 285 ([M–C6H11NO3S]+ •, 100), 242 394 
(40), 216 (25), 199 (25), 174 (45), 118 (20), 88 (45), 76 (50). m/z (ESI) = 463.1900 ([M+H]+, 395 
C23H31N2O6S gives 463.1903). 396 
Investigation of reaction kinetics by LC-MS: 397 
The enones and their adducts with N-acetyl-L-cysteine methyl ester were separated using an 398 
Agilent 1260 UHPLC system with an Agilent C18 column (50 mm with a 5 mm guard 399 
column, 2.1 mm diameter, 1.8 µm particle size). The mobile phase consisted of 86% aqueous 400 
ammonium acetate (10 mM) adjusted to pH 5.5 and 14% acetonitrile with a flow rate of 0.5 401 
mL min–1. Analytes were ionized by atmospheric pressure electrospray ionisation (AP-ESI) 402 
with an Agilent 6120 quadrupole mass spectrometer and ions were monitored in positive 403 
mode for the protonated species ([M+H]+). The capillary voltage was 1500 V and the 404 
fragmentor voltage was 150 V. 405 
Reactions were carried out in 10 mM HEPES buffer adjusted to pH 7.5 at 20 °C. A solution 406 
of the enone (1 eq) was mixed with a solution of N-acetyl-L-cysteine methyl ester (20 eq) and 407 
the composition of the mixture was analysed by LC-MS at regular intervals. The 408 
concentration of the enone at each interval was determined with reference to a calibration 409 
curve and the pseudo first order rate constant for the reaction was estimated by least squares 410 
curve fitting from the plot of enone concentration against time using KaleidaGraph. 411 
Investigation of reaction kinetics by 1H-NMR: 412 
Reactions were carried out in deuterated methanol at 25 °C. A solution of the enone (1 eq) 413 
was mixed with a solution of N-acetyl-L-cysteine methyl ester (20 eq) and the composition of 414 
the mixture was determined by 1H-NMR analysis at regular intervals. The concentration of 415 
the enone at each interval was determined by comparing the relative integration of the H-7 416 
olefinic proton in the starting material with the H12β benzylic proton in both the starting 417 
material and product. The pseudo first order rate constant for the reaction was estimated by 418 
least squares curve fitting from the plot of enone concentration against time using 419 
KaleidaGraph. 420 
Supporting Information: 421 
17 
Experimental procedures for compounds 4-7, 9, 10, 13, 15-19, together with 1H-NMR and 422 
13C-NMR spectra for all compounds and low resolution mass spectra for new compounds.  423 
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